Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study

Summary Background : Talazoparib is a poly(ADP-ribose) polymerase enzyme inhibitor. This open-label, non-randomized, phase 1 study of talazoparib investigated the safety, pharmacokinetics, and preliminary antitumor activity in Japanese patients with locally advanced or metastatic solid tumors, regar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2021-12, Vol.39 (6), p.1568-1576
Hauptverfasser:	Naito, Yoichi, Kuboki, Yasutoshi, Ikeda, Masafumi, Harano, Kenichi, Matsubara, Nobuaki, Toyoizumi, Shigeyuki, Mori, Yuko, Hori, Natsuki, Nagasawa, Takashi, Kogawa, Takahiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine diphosphate Adult Adverse events Aged Alanine Alanine transaminase Anemia Anticancer properties Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Antitumor activity Asians Constraining Disease control DNA damage DNA repair Dosage Dose-Response Relationship, Drug Enzyme inhibitors Humans Japan Leukocytes Leukocytes (neutrophilic) Maximum Tolerated Dose Medicine Medicine & Public Health Metastases Middle Aged Mutation Neoplasm Grading Neoplasm Metastasis Neoplasms - drug therapy Neoplasms - pathology Neutrophils Oncology Patients Pharmacokinetics Pharmacology Pharmacology/Toxicology Phase I Studies Phthalazines - administration & dosage Phthalazines - adverse effects Phthalazines - pharmacokinetics Phthalazines - therapeutic use Poly(ADP-ribose) Poly(ADP-ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage Poly(ADP-ribose) Polymerase Inhibitors - adverse effects Poly(ADP-ribose) Polymerase Inhibitors - pharmacokinetics Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Ribose Safety Solid tumors Stomatitis Targeted cancer therapy Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!